Velia Therapeutics is focused on uncovering and harnessing the therapeutic potential of previously overlooked proteins, specifically small proteins known as "microproteins," which are encoded in the human genome. The company has identified over 2,500 of these novel microproteins, emphasizing their significance in mediating diverse biological functions. By leveraging advanced technologies such as computational biology, human genetics, and automation, Velia aims to explore the complexities of the human proteome and translate these insights into transformative therapeutics. Their approach is characterized by a commitment to bold scientific inquiry and a focus on novel human targets that could significantly impact human health.

The leadership at Velia, particularly under Dr. John McHutchison, is dedicated to advancing the discovery of first-in-class therapies. The company prioritizes the development of innovative treatments that address critical disease drivers, aiming to create life-changing therapeutics for patients. Velia's foundational research has established a strong basis for their work, with a focus on translating early discoveries into impactful medical solutions. By fostering a culture of innovation and collaboration among top scientists, Velia Therapeutics is positioned at the forefront of biological research and therapeutic development.

United States

Velia was created to uncover the dark matter of the human proteome. Their scientific founders built the technologies to identify novel, protein coding sequences hidden within the human genome. Their pioneering work has uncovered the importance and therapeutic potential of these small proteins. To date, Velia has identified >2,500 novel “microproteins” and the list continues to grow. Early studies highlight that these small proteins mediate rich and diverse human biology.

Velia Therapeutics

Company Details